The weekly litigation news digest is live. Subscribe now

IP Verse

Patent Oppositions in mixed drugs industry

Explore the competitive field of mixed drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in mixed drugs technology and learn how to protect your intellectual property.

Get Patent Opposition Report for mixed drugs

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Report

Top companies filing patent oppositions

Explore the top companies that have filed the most patent oppositions in the technology industry.

Last updated on: Nov 20, 2025
CompanyTotal Oppositions
GENERICS UK43
TEVA PHARMACEUTICALS38
SANDOZ24
STADA ARZNEIMITTEL21
ALFRED E TIEFENBACHER15
ELKINGTON AND FIFE14
KRAUS & LEDERER PARTGMBB13
HEXAL11
HAMM & WITTKOPP11
MAIWALD11

Top companies facing patent oppositions

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Nov 20, 2025
CompanyTotal Oppositions
NOVARTIS65
BOEHRINGER INGELHEIM38
GLAXO GROUP22
JANSSEN ONCOLOGY22
F HOFFMANN LA ROCHE22
COUGAR BIOTECHNOLOGY22
NESTLE14
SALIX PHARMACEUTICALS14
NUTRICIA13
AVENTIS PHARMA13

Top active law firms filing patent oppositions

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Last updated on: Nov 20, 2025
Law FirmTotal Oppositions Filed
ELKINGTON AND FIFE68
HAMM & WITTKOPP57
TER MEER STEINMEISTER & PARTNER39
D YOUNG24
MAIWALD22
KRAUS & LEDERER PARTGMBB21
HOFFMANN EITLE20
LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBB9
BRAND MURRAY FULLER9
BARDEHLE PAGENBERG SL9

Latest patents opposed in the mixed drugs industry

Patent challenges are becoming increasingly common in the mixed drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the mixed drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Nov 20, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name
EP3982992
Use Of Whey Protein Micelles For Controlling Postprandial Glucose ResponseNESTLEOct 15, 2025ARLA FOODS AMBA
EP4370116
Methods For Treating Hypertrophic CardiomyopathyCYTOKINETICSOct 14, 2025HAMM & WITTKOPP
EP3982992
Use Of Whey Protein Micelles For Controlling Postprandial Glucose ResponseNESTLEOct 13, 2025FRESENIUS KABI DEUTSCHLAND
EP4188327
Combination Therapy For Inhalation AdministrationCHEMO RESEARCHOct 1, 2025HIGHTONE MANAGEMENT
EP3246047
Combination DrugCHUGAI SEIYAKU KABUSHIKI KAISHASep 24, 2025BOTTI & FERRARI
EP3542638
Nutritional CompositionNUTRICIASep 23, 2025NESTLE
EP3542638
Nutritional CompositionNUTRICIASep 22, 2025ABBOTT
EP3321270
Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-OlateGILEAD SCIENCESSep 4, 2025ELKINGTON AND FIFE
EP3321270
Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-OlateGILEAD SCIENCESSep 3, 2025SANDOZ
EP3321270
Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-OlateGILEAD SCIENCESSep 2, 2025HAMM & WITTKOPP

Top patents facing oppositions in mixed drugs industry

To stay ahead in the competitive mixed drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the mixed drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Nov 20, 2025
Patent NumberPublication DateTitleApplicantTotal Oppositions
EP2478907
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
EP4321157
Oct 23, 2024New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS18
EP3626270
Oct 11, 2023New UseNOVARTIS17
EP2493466
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI13
EP3494972
Dec 13, 2023Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv InfectionVIIV HEALTHCARE10
EP2981255
Sep 14, 2022Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIM10
EP2766040
May 15, 2019Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHE9
EP3038654
Oct 30, 2019New UseNOVARTIS9
EP2350096
Dec 11, 2019Methods Of Treating Hepatic EncephalopathySALIX PHARMACEUTICALS8
EP2928496
Oct 9, 2019Crispr-Based Genome Modification And RegulationSIGMA ALDRICH8